You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Bronchiectasis Update: Evaluation, Clinical Course, Inflammation, and Treatment

  • Authors: Charles L. Daley, MD; Jeffrey B. Hoag, MD; Steven E. Lommatzsch, MD; Sarah Taimur, MD
  • CME Released: 11/30/2022
  • Valid for credit through: 11/30/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

Primary care physicians, pulmonologists, radiologists, as well as nurse practitioners and physician assistants in those specialties.


This program will focus on assessment of non-cystic fibrosis bronchiectasis (NCFBE) and approaches to reduce delay in diagnosis. Attendees will become more adept at assessing patients' natural history, clinical course, and disease progression and gain a deeper understanding of the role of neutrophilic inflammation and neutrophil serine protease (NSP) inflammation in NCFBE. Lastly, this session will explore current and emerging therapies to optimize clinical outcomes in patients with NCFBE.


Upon completion of this activity, participants will:

  1. Review bronchiectasis burden, etiologies, and best practice evaluation strategies
  2. Describe the clinical course and progression of bronchiectasis
  3. Describe the role of neutrophilic inflammation in patients with bronchiectasis
  4. Identify current and emerging treatments for patients with bronchiectasis


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or absence of any relevant financial relationships with an ACCME-defined ineligible company within the preceding 24 months of the activity. The ACCME defines an “ineligible company” as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


Our goal is to ensure that there is no compromise in the ethical relationship that exists between those in a position to control the content of the activity and those participating in the activity and their respective professional duties. All accredited education activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.


All relevant financial relationships among individuals in a position to control the content of this activity have been identified and mitigated according to the Standards of Integrity and Independence in Accredited Continuing Education.


Unlabeled and Investigational Usage


The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.


No endorsement of unapproved products or uses is made or implied by coverage of these products or uses.


Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.


Disclaimer Statement


National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.


By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.


Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.


Chair

  • Steven E. Lommatzsch, MD

    Associate Professor of Medicine
    Director, Non-CF Bronchiectasis Program
    Division of Pulmonary, Critical Care
    Department of Medicine
    National Jewish Health
    Denver, Colorado

    Disclosures

    Steven E. Lommatzsch, MD, has no relevant financial relationships.

Faculty

  • Charles L. Daley, MD

    Chief
    Division of Mycobacterial & Respiratory Infections
    Professor
    Department of Medicine
    National Jewish Health
    Denver, Colorado

    Disclosures

    Charles Daley, MD, has the following relevant financial relationships:
    Consultant or advisor for: AN2; Hyfe; Insmed; Matinas; Paratek; Spero
    Investigator for: AN2; Insmed; Paratek

  • Jeffrey B. Hoag, MD

    Associate Professor of Medicine
    Section Chief, Jefferson Northeast
    Division of Pulmonary, Allergy and Critical Care Medicine
    The Jane and Leonard Korman Respiratory Institute
    Jefferson Health and National Jewish Health
    Sidney Kimmel Medical College
    Thomas Jefferson University
    Philadelphia, Pennsylvania

    Disclosures

    Jeffrey B. Hoag, MD, has no relevant financial relationships.

  • Sarah Taimur, MD

    Associate Professor of Medicine
    Division of Infectious Diseases
    The Mount Sinai – National Jewish Health Respiratory Institute
    Icahn School of Medicine at Mount Sinai
    New York, New York

    Disclosures

    Sarah Taimur, MD, has no relevant financial relationships.

  • Planners and Reviewers

    Meghan Brenner, MA, has no relevant financial relationships.


    Edward Chan, MD, has no relevant financial relationships.


    Mandy Comeau has no relevant financial relationships.


    Andrea Harshman, MHA, CHCP, CMP-HC, has no relevant financial relationships.


    Steven E. Lommatzsch, MD has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
     

    National Jewish Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of  75%  on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, accreditation information, and disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Bronchiectasis Update: Evaluation, Clinical Course, Inflammation, and Treatment

Authors: Charles L. Daley, MD; Jeffrey B. Hoag, MD; Steven E. Lommatzsch, MD; Sarah Taimur, MDFaculty and Disclosures

CME Released: 11/30/2022

Valid for credit through: 11/30/2023

processing....

Learning Feedback Questions

Before you begin, please take this brief survey.

  • Print